Aimed at senior scientists and respiratory and inhalation specialists, Asthma & COPD 2017 will reflect on the ongoing issues and latest developments of these two diseases.
With a carefully selected panel of industry experts, the 2017 event will address the latest challenges and changes in the fields of asthma and COPD. The agenda will explore novel approaches to treatment, including cutting edge developments in triple combination therapies and phenotyping. As well as identify challenges to device development and delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.
Featured Speakers:
Quan Yang, Pharmaceutical Assessor, MHRA
Stephen Beckman, Head of Global Respiratory and Allergy, Mylan
Outi Vaarala, Vice President, Head of Translational Biology, AstraZeneca
Ewan Walters, Medical Director, Teva UK
David Leather, Global Medical Affairs Leader, GlaxoSmithKline
Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals
Christopher Stevenson, Venture Leader COPD Interception, Janssen
Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca
Frank Thielmann, Operational Lead Inhalation New Solids, Novartis
and many more...
Exclusive highlights in 2016:
Updates from the MHRA on the regulatory challenge to developing inhalation devices
Overcome hurdles to the success of new devices with Boehringer Ingelheim
Janssen’s innovative approaches to COPD interception
Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune
Real time data collection’ – an exclusive case study presentation on GSK’s pioneering ‘Salford Lung study’
WORKSHOPS:
Both interactive workshops have been carefully selected to complement the topics covered in the conference agenda.
With a carefully selected panel of industry experts, the 2017 event will address the latest challenges and changes in the fields of asthma and COPD. The agenda will explore novel approaches to treatment, including cutting edge developments in triple combination therapies and phenotyping. As well as identify challenges to device development and delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.
Featured Speakers:
Quan Yang, Pharmaceutical Assessor, MHRA
Stephen Beckman, Head of Global Respiratory and Allergy, Mylan
Outi Vaarala, Vice President, Head of Translational Biology, AstraZeneca
Ewan Walters, Medical Director, Teva UK
David Leather, Global Medical Affairs Leader, GlaxoSmithKline
Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals
Christopher Stevenson, Venture Leader COPD Interception, Janssen
Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca
Frank Thielmann, Operational Lead Inhalation New Solids, Novartis
and many more...
Exclusive highlights in 2016:
Updates from the MHRA on the regulatory challenge to developing inhalation devices
Overcome hurdles to the success of new devices with Boehringer Ingelheim
Janssen’s innovative approaches to COPD interception
Track the emerging trends in targeted treatment with biomarkers and biologics with MedImmune
Real time data collection’ – an exclusive case study presentation on GSK’s pioneering ‘Salford Lung study’
WORKSHOPS:
Both interactive workshops have been carefully selected to complement the topics covered in the conference agenda.
